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precision cancer monitoring using a 
novel, fully integrated, microfluidic 
array partitioning digital pcR 
platform
Megan e. Dueck1*, Robert Lin1, Andrew Zayac1, Steve Gallagher1, Alexander K. chao2, 
Lingxia Jiang1, Sammy S. Datwani1, paul Hung1 & elliot Stieglitz  2,3
A novel digital PCR (dPCR) platform combining off-the-shelf reagents, a micro-molded plastic 
microfluidic consumable with a fully integrated single dPCR instrument was developed to address 
the needs for routine clinical diagnostics. This new platform offers a simplified workflow that enables: 
rapid time-to-answer; low potential for cross contamination; minimal sample waste; all within a single 
integrated instrument. Here we showcase the capability of this fully integrated platform to detect and 
quantify non-small cell lung carcinoma (NSCLC) rare genetic mutants (EGFR T790M) with precision 
cell-free DNA (cfDNA) standards. Next, we validated the platform with an established chronic myeloid 
leukemia (CML) fusion gene (BCR-ABL1) assay down to 0.01% mutant allele frequency to highlight the 
platform’s utility for precision cancer monitoring. thirdly, using a juvenile myelomonocytic leukemia 
(JMML) patient-specific assay we demonstrate the ability to precisely track an individual cancer 
patient’s response to therapy and show the patient’s achievement of complete molecular remission. 
These three applications highlight the flexibility and utility of this novel fully integrated dPCR platform 
that has the potential to transform personalized medicine for cancer recurrence monitoring.
It is becoming increasingly accepted that while Next Generation Sequencing (NGS) is an invaluable tool for broad 
based sequence characterization, its precision in tracking rare mutant events is low. In a recent study, Stetson et al.1  
indicated that NGS is only accurate in quantification of rare mutant burdens that are >1%. Digital PCR offers 
clinicians the necessary tool for absolute quantification and enhanced precision tracking of ultra-rare (<1%) 
mutations.
The concept of Digital Polymerase Chain Reaction (dPCR) was first published by Saiki et al. in 1988 high-
lighting a Poisson distribution of individual PCR target sequences2 with Volgelstein et al., later coining the term 
“Digital PCR”3. Unlike the popular quantitative PCR (qPCR) where PCR templates are quantified by comparing 
the rate of PCR amplification of an unknown sample to the rate of a set of known qPCR standards, dPCR has been 
proven to exhibit higher sensitivity4, higher precision5 and improved reproducibility6. The advent of microfluidics 
has greatly aided the advancement of dPCR; however, current available partitioning technologies suffer from limi-
tations in three critical areas – low partition volume consistency, low partition number consistency and high dead 
volume of loaded sample. Droplet-based dPCR technologies7–9 have innate issues with droplet-to-droplet volume 
uniformity that can affect the accuracy of quantification, impact reproducibility and hinder conformance to clini-
cal regulatory requirements. Reagent partitioning that requires user-controlled moving parts or user-applied thin 
films on the consumable10–12 can create non uniformity in partition size. Partition and volume non-uniformity, as 
well as the potential for instrument contamination will likely be obstacles preventing other dPCR platforms from 
transitioning from research-use to the clinic. Furthermore, variable partition volumes result in variable distribu-
tion of targets inside the partitions, thus undermining the mathematical basis of dPCR and downstream analysis. 
Fluctuating partition numbers underscore the instability of the partitioning process and introduce unnecessary 
variables into the assay and limit sensitivity. Unanalyzed sample via a high dead volume in the consumable intro-
duces subsampling error and reduces the overall accuracy of the results. Subsampling error is a function of both 
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the expected target concentration as well as the degree of subsampling. The combination of rare targets with high 
dead volume synergistically lowers dPCR accuracy and broader based applicability for clinical applications.
Here we present a novel Microfluidic Array Partitioning (MAP) consumable device that utilizes precisely 
manufactured high volume injection molded arrays combined with precise fluidic control to overcome cur-
rent dPCR limitations. The high-volume injection molding process ensures that all partitions have a consistent 
and well-defined sample volume. The partition size is defined by the physical limitation of the microarray wells 
and not by a stochastic process. The partition array consists of a fixed geometry and ensures a consistent num-
ber of partitions for all samples across each experimental run. The number of partitions is defined by the array 
geometry and is minimally susceptible to the variation in the partitioning process. Coupled with a novel precise 
fluidic loading process, the MAP consumable device utilizes >95% of input sample and significantly reduces 
subsampling error compared to other currently available technologies that utilize <80% of the loaded sample. 
For example, in the BioRad QX200 ddPCR system users routinely only generate between 11,000 and 16,000 ana-
lyzable droplets per sample out of a possible 20,00013. This means that users are only analyzing between 55% and 
80% of their loaded sample.
To address the needs of adopting dPCR as a routine tool for personalized medicine, a complete clinic-friendly 
single instrument dPCR integrated platform was developed. This dPCR platform was designed for simplified 
workflows, a reduction in contamination potential and rapid time-to-answer. Using three unique cancer-specific 
applications we have highlighted the platform’s versatility to perform precision, personalized cancer biomarker 
monitoring.
Results
novel fully integrated single instrument dpcR platform. The novel dPCR platform consists of a 
micro-molded plastic Microfluidic Array Partitioning (MAP) consumable device (Fig. 1) and a fully integrated 
single instrument that combines pneumatic consumable sample loading, thermal cycling, 3-color fluorescence 
image acquisition with control and analysis software (Fig. 2, Supplemental Fig. 1). The combination of the MAP 
consumable and fully integrated single instrument creates a streamlined workflow, reduces the potential for con-
tamination, minimizes human handling errors and has a unique capability to decrease the time to result. The 
low thermal mass of each microchamber (<1 ng) allows for fast dPCR thermal cycling with reduced dwell times. 
Since the micro-molded dPCR partitions are shallow (X = 65 µm, Y = 82 µm, Z = 97 µm in height) and located 
directly above the thermal-cycling heating element (separated only by a 40 µm thin film from STRATEC Inc., 
Anif, Austria), sample results can be obtained using <15% of the standard thermal cycling dwell times as com-
pared to standard tube-based thermal cycling of droplet based dPCR aggregates (Supplemental Fig. 2). 95 °C 
PCR enzyme activation can be achieved in 60 seconds (10 minutes recommended), and complete thermal-cycling 
can be achieved with 40 cycles of 60 °C for 15 seconds followed by 95 °C for 4 seconds. Low thermal mass is an 
advantage in a system such as this as it reduces the reaction time from the input of energy to deliver a change in 
temperature, thus enabling better control, as previously demonstrated by Amasia et al.14 and Farrar et al.15. The 
combination of active heating and low thermal mass synergistically enables faster rates of temperature ramp while 
still maintaining uniform temperature profiles across the MAP consumable. These combined features allow this 
novel platform to achieve sample-to-answer in <90 minutes with no change to reagent composition.
The MAP consumable partitions each sample into 20,000 micromolded array wells without the need for 
valves, user-applied films or any moving parts. After the user pipettes 10.5 µL of bulk PCR reagent into a MAP 
consumable inlet, the user next overlays 5 µL of silicone oil into the same inlet well. After these two liquid han-
dling steps (which can be automated), the inlet wells are capped (and hence closed off) with specialized caps that 
allow for positive pressure to pass through. The consumable is then loaded into the instrument where the auto-
mated loading protocol is initiated. Figure 2 shows a photograph of the interior of the integrated platform as well 
Figure 1. Microfluidic Array Partitioning (MAP) digital PCR (dPCR) consumable. (A) Photograph of the MAP 
consumable. The full micro-molded Cyclo Olefin Polymer (COP) is 1″ × 3″ and contains 4 arrays of 20,000 
partitions each. (B,C) Scanning Electron Micrograph (SEM) images of the MAP consumable partitions. After 
the automated reagent loading and digitization step, the arrayed partitions (X = 65 µm, Y = 82 µm, Z = 97 µm 
in height) are filled with reagent and the thinner connecting channels (10 µm in height, 25 µm in width) are 
next filled with silicone oil (creating fluidically isolated partitions). (D) A fluorescent image of the raw dPCR 
experimental results processed from a MAP consumable. PCR reagents containing a FAM-labeled probe and a 
reference dye (ROX) were loaded into the consumable and then thermal-cycled per user pre-defined settings. 
The consumable was next imaged in both the ROX and FAM channels. Finally, these two images were then 
overlaid where the red (ROX channel) represents partitions in which the reagent successfully loaded but no 
PCR target was present and the green (FAM channel) represents partitions that contained the PCR target.
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as a workflow chart indicating the sample loading and analysis steps. Additional details on the construction of the 
instrument as well as the optical set-up can be found in the supplement (Supplemental Fig. 1).
The mechanism by which the MAP consumable is loaded relies upon the 40 µm thin Cyclo Olefin 
Polymer (COP) film to which the micromolded features are bonded. When positive pressure is applied to a 
reagent-containing inlet well this 40 µm thin film becomes gas permeable. As the reagent enters the microfluidic 
features, air is outgassed through the thin film. This allows reagent to completely fill dead-ended features such as 
the dPCR partitions and also removes all bubbles from inside of the microfluidic features (Fig. 3). First the reagent 
enters the shallow connecting channels adjacent to the partitions, next the reagent enters and fills the partitions, 
then oil that was overlaid on the reagent in the inlet well enters the connecting channel and successively fluidically 
Figure 2. The prototype of the fully-integrated single dPCR instrument. The photographic image shows the 
various subassemblies and instrument components of the integrated dPCR instrument. The flowchart below 
represents the simplified workflow where the instrument carries out the reagent partitioning step, followed by 
the thermal cycling process and finally the results are acquired and software processes the results in a simple one 
step workflow.
Figure 3. Principle of digitization in MAP consumable. (A) MAP consumable brightfield microscopy image 
accompanied by a cross-section depiction of channel heights. (B) The MAP consumable is loaded by applying 
positive pressure to an inlet well that has been loaded with reagent then overlaid with silicone oil. First the 
reagent (fluorescent orange) enters the connecting channels adjacent to the partitions. Next the reagent dead-
end fills the partitions by outgasing air through the semi gas-permeable thin film. Finally the silicone oil (not 
visible) enters the connecting channel and fluidically isolates each partition as it passes.
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isolates each partition that it passes. Complete filling of partitions was verified using high resolution fluorescence 
microscopy (Fig. 3). Partition loading success (% of partitions fully loaded) was found to be >98%. Using a 3D 
surface profiler (Keyence; Itasca, IL) each partition was found to be 65 µm × 82 µm × 97 µm with a volume of 
517 pL. Thus, the total volume of reagent in the 20,000 microwell array after digitization is 10.34 µL. Given our 
partition fill success rate, this means that over 95% of the 10.5 µL of reagent loaded into the inlet well is analyzed 
in our partition array. Positive pressure directed into the consumable during the full PCR process ensures new 
bubbles will not form.
The loading of the MAP consumable and the reagent partitioning is accomplished in one instrument by apply-
ing positive air pressure to the inlet well with a pneumatic pump (Parker Instrument, standard diaphragm pump; 
Huntsville, AL). The cap applied on the inlet well prevents the instrument from contacting any potentially con-
taminated surfaces. Positive displacement pressure of 50 psi directed into the MAP consumable throughout the 
workflow ensures that no aerosolized contaminants will enter the instrument. This novel fully integrated instru-
ment is dry, contamination-free and requires no routine maintenance to allow for the potential to transition to 
routine clinical use.
Fully automated software controls the sample digitization into the MAP partitions, thermal cycling and 
imaging. The partition arrays are imaged before and after PCR thermal cycling in each of the fluorescent dye 
colors enabling the analysis software to subtract the background fluorescence and correct for non-uniform 
excitation. A ROX quality control dye that is added to the PCR reaction mix is visible in all partitions and used 
to confirm the sample was loaded completely and to locate each partition. Partitions without a ROX signal are 
rejected to reduce the number of false negatives. For each PCR probe dye color, partitions with a significant 
increase in brightness after PCR thermal cycling are considered positive. The ratio of positive partitions relative 
to the total number of partitions is used to calculate the sample concentration by applying a Poisson distribu-
tion analysis. To initially verify the capabilities of our system, pre-quantified standards from a Next Generation 
Sequencing (NGS) library quantification kit were run (Takara Cat No. 638324). Quantitative results from the 
novel platform showed great linearity across dilutions and also small coefficients of variation across replicates 
(Supplemental Fig. 3).
EGFR T790M rare mutant quantification. EGFR is an important drug target for the treatment of 
non-small cell lung carcinoma (NSCLC). During the treatment of NSCLC with tyrosine kinase inhibitors (TKIs), 
there is typically an early response, followed by relapse upon outgrowth of a pre-existing subclonal mutation or 
the acquisition of a de-novo mutation that confers resistance. Early detection of resistance mutations can better 
inform patient treatment and guide appropriate more efficacious drug selection. One key EGFR mutation that 
leads to TKI resistance is the T790M mutation. There are only a few clinical assays that have been approved as 
companion diagnostics in patient biopsies (FFPE or plasma), while a larger number of laboratory developed tests 
(LDTs) under CLIA/CAP guidance are finding routine use in cancer disease diagnosis or cancer treatment mon-
itoring. EGFR T790M mock cell-free DNA (cfDNA) standards (SeraCare, SeraSeq ctDNA) in combination with 
a commercially available EGFR T790M dPCR assay (Bio-Rad, ddPCR assay) were used to validate the novel plat-
form presented in this study. The cfDNA standards tested were synthetically manufactured, fragmented and then 
blended with well-characterized background material to fully mimic cfDNA that would be purified from a patient 
blood sample. Premixed PCR reagent containing mastermix, the EGFR T790M dPCR assay and the following 
cfDNA standards were run in triplicate units on the platform: 100% wild-type(WT) EGFR, 1.0% EGFR T790M 
and 0.1% EGFR T790M (Fig. 4). All replicates for the WT EGFR only control showed no positive partitions in 
the T790M (FAM) channel showing that the probe was specific to the WT amplicon and that there was no optical 
crosstalk into the FAM channel. Thresholds for positives in both the FAM and HEX channels were set using the 
no template control. For the 0.1% and 1% EGFR T790M samples, concentrations were generated for both WT 
EGFR and EGFR T790M. For example, in one of the triplicate runs using the 0.1% T790M sample, the concen-
tration of WT EGFR derived by the platform was 1006 Cp/µL and 1.3 Cp/µL for EGFR T790M. Therefore, the 
fraction of EGFR T790M: WT for this run was determined to be 0.13%. The Seraseq synthetic cfDNA standards 
are generated to be fragmented in a manner similar to human cfDNA. As such, small discrepancies between the 
nominal values supplied by the vendor (e.g.: 0.1%) and those achieved on the novel dPCR platform (e.g.: 0.13%) 
could be explained by the fragmentation process used to generate the synthetic samples. These results show the 
novel dPCR platform’s capability to precisely quantify samples containing <1.0% T790M EGFR in a background 
of WT EGFR with high reproducibility, high accuracy and high specificity.
BCR-ABL1 rare transcript quantification. Nearly 95% of chronic myeloid leukemia (CML) cases are 
characterized by the presence of the BCR-ABL1 fusion gene. Wild type (WT) ABL1 is a tyrosine kinase that 
plays a role in cell cycle regulation and cellular differentiation. The expression of the BCR-ABL1 fusion onco-
gene generates a constitutively active tyrosine kinase leading to uncontrolled cellular proliferation and eventually 
cancer. The advent of tyrosine kinase inhibitor (TKI) therapy has had a transformative effect on CML patient 
outcomes. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful 
TKI treatment, occasionally leading to drug discontinuation upon achievement of deep remissions. The current 
gold standard for clinical BCR-ABL1 transcript quantification is Reverse Transcription Quantitative Polymerase 
Chain Reaction (RT-qPCR). A well-characterized single-plex RT-qPCR BCR-ABL1 assay was previously modi-
fied by Alikian et al.16 to a duplex dPCR assay. Using this dPCR assay, synthetic gBlocks (double stranded DNA 
fragments) for both ABL1 and BCR-ABL1 were quantified to determine their nominal concentrations (Fig. 4). 
These synthetic gBlock samples were quantified on the dPCR platform using a FAM-labeled BCR-ABL1 probe 
and HEX-labeled ABL1 probe. Running the gBlock templates separately showcases the lack of optical cross-talk 
using the dPCR platform: when pure WT ABL1 gBlock is run there are no positive partitions in the FAM channel, 
when pure BCR-ABL1 gBlock is run there are no positive partitions in the HEX channel (Fig. 5). To showcase 
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the linearity of our results, a 10X dilution series of BCR-ABL1 gBlock was also run on the system (Supplemental 
Fig. 4). Thresholds for positives in both the FAM and HEX channels were set using the no template control for 
all samples. These experimentally derived nominal gBlock concentrations were then used to generate samples 
with precise ratios of synthetic BCR-ABL1 to ABL1 which were then run on the novel dPCR platform (Fig. 6). 
For example, in one of the triplicate experimental runs using a 0.01% BCR-ABL1/ABL1 sample, the concentra-
tion of WT ABL1 derived by the platform was 10,252 Cp/µL and 1.2 Cp/µL for BCR-ABL1. Thus, the fraction 
of BCR-ABL1/ABL1 for this run was determined to be 0.0117%. Replicate measurements for this same sample 
were found to be 0.0099% and 0.0089% indicating high reproducibility and high precision. This showcases the 
platform’s ability to precisely quantify BCR-ABL1 transcripts down to a 0.01% mutant allele frequency with high 
reproducibility across triplicate runs.
Personalized cancer monitoring using a patient-specific dPCR assay. To demonstrate the platform’s 
potential utility in personalized medicine, a droplet digital PCR (ddPCR) assay that was previously designed for 
precision monitoring of a specific patient was replicated on the novel digital PCR platform. Juvenile myelomono-
cytic leukemia (JMML) is an aggressive myeloproliferative neoplasm of childhood with nearly half of all patients 
relapsing within three years17,18. A seven-week-old boy diagnosed with JMML was shown to have WT status for all 
known JMML mutations. Both an institutional DNASeq panel and RNASeq revealed an inframe CCDC88C-FLT3 
fusion19. Prior to this discovery, FLT3 fusions had not been reported in any pediatric malignancy. Given the nov-
elty of this CCDC88C-FLT3 fusion, no commercial assays were available to identify fusion transcripts below the 
sensitivity of cytogenetics. As such, the oncologist designed a specific ddPCR assay to analyze the abundance of 
this CCDC88C-FLT3 fusion in peripheral blood RNA over serial time points18. This ddPCR-based method for 
monitoring the patient’s response to Sorafenib (Nexavar) enabled the patient to proceed safely to hematopoietic 
stem cell transplantation (HSCT) and eventually achieve a complete molecular remission.
Replicating this assay on the prototype dPCR platform with bio-banked samples from the same patient 
revealed that the fusion transcript levels in the patient’s peripheral blood did not decrease following cytotoxic 
chemotherapy but then dropped following Sorafenib monotherapy and reached undetectable levels following 
HSCT (Fig. 7). Thresholds for CCDC88C-FLT3 fusion positive dPCR partitions were set using the no template 
control. All measurements post-HSCT were true negatives on the novel dPCR platform, showing zero positive 
partitions containing the CCDC88C-FLT3 fusion target. These results replicated the trends achieved with this 
Figure 4. EGFR T790M rare mutant quantification. The reagent was prepared to contain either no template, 
WT EGFR only, 1% EGFR T790M in a background of WT EGFR or 0.1% EGFR T790M in a background of WT 
EGFR. The reagent also contained a FAM-labeled EGFR T790M probe along with a HEX-labeled WT EGFR 
labeled probe. This reagent was loaded into a MAP consumable and processed on the prototype integrated 
dPCR instrument. A scatter plot of the results show the individual partition fluorescence on the y-axis and 
partition number on the x-axis (where each data point represents the results from an individual partition). The 
two tables show the results from measurements in triplicate for the 1.0% and 0.1% EGFR T790M samples.
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assay and samples from this patient using a commercially available ddPCR platform19 indicating a high level of 
concordance. This personalized medicine approach to precision monitoring of patient-specific biomarkers show-
cases the potential for dPCR as a powerful tool for companion diagnostics.
Discussion
Here we have presented a novel fully integrated digital PCR platform that was designed to facilitate the adop-
tion of dPCR for precision oncology-based diagnostics. We have showcased the platform’s utility for quantifying 
<1.0% mutant burden using two clinically relevant applications (EGFR T790M and BCR-ABL1). Furthermore, 
we demonstrated the utility of this platform for a personalized medicine application by replicating a published 
clinical study that tracked a patient’s transition to complete molecular remission using a custom, patient-tailored 
dPCR assay.
Finally, the MAP consumable and fully integrated single system dPCR platform presented is the first of its 
kind that has potential to allow for real-time and melt-based analysis of digital PCR partitions. Melt-based multi-
plexing is the key to unlocking the potential for dPCR to produce higher plex quantitative assays, allowing clini-
cians to precisely quantify panels of 10 or more nucleic acid biomarkers per sample run. In fact, it has previously 
been shown that a computer can be trained to recognize 89 unique, amplicon-specific PCR melt-signatures20. 
Future integration of our dPCR platform with artificial intelligence (AI) and machine learning could ena-
ble unparalleled dPCR multiplexing capabilities.  Real-time monitoring is also critical for improving assay devel-
opment and can be used to improve partition classification over traditional endpoint dPCR alone. Real time 
measurement of dPCR partitions can potentially remove the need for arbitrary thresholding entirely. These fea-
tures combined with dPCR’s innate ability to quantify ultra-rare (<1.0%) genetic events will unlock the power of 
dPCR for precision cancer monitoring and for improving patient outcomes to advance human health.
Methods
MAp consumable fabrication. MAP consumables were micro-injection molded with high optical clarity 
Cyclo-Olefin Polymer (COP) (Zeon chemical) and sealed with a thermoplastic thin film. Using con-focal laser 
interferometry, the devices have shown dimensional variability within ±0.1 µm in planar and ±1.0 µm in height, 
which translated to ±1.5% total volume variation. In addition, a lamination strength study was conducted to 
show that the devices could withstand over 100 Psi pressure without delamination for over 24 hours.
EGFR T790M rare mutant quantification. Seraseq® ctDNA EGFR T790M reference standards with 
nominal (company provided) values were acquired from SeraCare (Seraseq ctDNA EGFR T790M MM AF0.1% 
Figure 5. BCR-ABL1 and ABL1 synthetic gBlock nominal concentration determination. The reagent was 
prepared to contain either ABL1 gBlock solution as template or BCR-ABL1 gBlock as template. The reagent 
also contained both a FAM-labeled BCR-ABL1 probe in addition to a HEX-labeled ABL1 probe. This reagent 
was then loaded into a MAP consumable and an experimental run was carried out on the prototype dPCR 
instrument. A scatter plot of the results show HEX fluorescence on the y-axis and FAM fluorescence on the 
x-axis (where each data point represents the results from an individual partition). The two tables contain the 
averaged results of the measurements in triplicate for the individual gBlock templates.
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Cat. 0710–0707, Seraseq ctDNA EGFR T790M MM AF1% Cat. 0710–0706, Seraseq ctDNA MM WT Cat. 0710–
0705; Milford, MA). These reference standards were used as the template in dPCR reactions containing a com-
mercially available EGFR T790M dPCRassay (Bio-Rad ddPCR Assay EGFR T790M Cat. 1016323 and Bio-Rad 
ddPCRAssay EGFR WT for T790 Cat. 1016326; Hercules, CA). The probe for EGFR WT fluoresces in the HEX 
channel, whereas the probe for T790M fluoresces in the FAM channel. Primers, probes and Seraseq template 
were combined with the following dPCR master mix and ROX loading control dye: QuantStudio 3D Digital PCR 
Master Mix v2 (ThermoFisher Cat. A26358; Waltham, MA), ROX Reference Dye (Biotium Cat. #29052; Fremont, 
CA). Once mixed, 10.5 µL of the complete dPCR reagent was loaded into an inlet well on the consumable and 
overlaid with 5 µL of silicone oil (Sigma Cat. 378321; St. Louis, MO). In the final reagent mix the mastermix was 
diluted 2X, the ROX dye 100X, the primer/probe assay mix 20X, the template 10X, then brought up to volume 
with water. After the instrument had completed the reagent digitization, the consumable was thermal-cycled 
using the following program: 1 cycle of 95 °C for 1 minute, 40 cycles of 95 °C for 4 seconds followed by 60 °C for 
18 seconds. After running this program the instrument captured images of the various partition arrays using 3 
filter sets: ROX, FAM and HEX.
BCR-ABL1 rare transcript quantification. Primer, probe and full amplicon sequences for both the 
BCR-ABL1 and ABL1 dPCR targets were derived from the study by Alikian et al. (2017). Primers, probes and 
full BCR-ABL1 and ABL1 template sequences (as synthetic double stranded DNA gBlocks) were custom ordered 
from Integrated DNA Technologies (Coralville, IA). The probe for ABL1 fluoresces in the HEX channel, whereas 
Figure 6. Quantification of precise BCR-ABL1/ABL1 ratios. Using the nominal gBlock concentrations 
determined prior, precise combinations of gBlock were generated to contain either 1%, 0.1% or 0.01% BCR-
ABL1 gBlock in a background of ABL1 gBlock. The reagent was prepared to contain one of these combinations 
as the template. The reagent also contained both a FAM-labeled BCR-ABL1 probe in addition to a HEX-labeled 
ABL1 probe. This reagent was loaded into a MAP consumable and run on the prototype dPCR instrument. 
A scatter plot of the experimental results show HEX fluorescence on the y-axis and FAM fluorescence on the 
x-axis (where each data point represents the experimental results from an individual partition). The three tables 
show averaged results from measurements in triplicate for the individual gBlock combinations: 1%, 0.1% and 
0.01% BCR-ABL1.
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the probe for BCR-ABL1 fluoresces in the FAM channel. Primers, probes and gBlock template were combined 
with the following dPCR master mix and ROX loading control dye: QuantStudio 3D Digital PCR Master Mix v2 
(ThermoFisher Cat. A26358; Waltham, MA), ROX Reference Dye (Biotium Cat. #29052; Fremont, CA). In the 
final reagent mix the mastermix was diluted 2X, the ROX dye 100X, the primer/probe assay mix 20X, the template 
10X, then brought up to volume with water. Once mixed, 10.5 µL of the complete dPCR reagent was loaded into 
an inlet well on the consumable and overlaid with 5 µL of silicone oil (Sigma Cat. 378321; St. Louis, MO). After 
the instrument had completed the reagent digitization, the consumable was thermal-cycled using the following 
program: 1 cycle of 95 °C for 1 minute, 40 cycles of 95 °C for 4 seconds followed by 60 °C for 18 seconds.. After 
running this program the instrument captured images of the various partition arrays using 3 filter sets: ROX, 
FAM and HEX.
Personalized cancer tracking using patient-specific dPCR assay. Primers and FAM-labeled 
probes were designed to amplify and detect CCDC88C-FLT3 fusion cDNA templates according to the methods 
described by Chao et al. (2019). RNA was extracted from peripheral blood and bone marrow using the RNeasy kit 
(Qiagen Cat. 74104, Hilden, Germany) and 100 ng RNA was reverse transcribed using the Maxima H Minus RT 
kit (ThermoFisher Cat. K1681; Waltham, MA) and used as a template for dPCR. To prepare the dPCR reactions, 
a mastermix was prepared using equivalent to 10 ng RNA of cDNA per 10.5 µL reaction. Primers, probes and 
cDNA template were combined with the following dPCR master mix and ROX loading control dye: QuantStudio 
3D Digital PCR Master Mix v2 (ThermoFisher Cat. A26358; Waltham, MA), ROX Reference Dye (Biotium Cat. 
#29052; Fremont, CA). In the final reagent mix the mastermix was diluted 2X, the ROX dye 100X, the primer/
probe assay mix 20X, the template 10X, then brought up to volume with water. Once mixed, 10.5 µL of the com-
plete dPCR reagent was loaded into an inlet well on the consumable and overlaid with 5 µL of silicone oil (Sigma 
Cat. 378321, St. Louis, MO). After the instrument has completed the reagent digitization, the consumable was 
thermal-cycled using the following program: 1 cycle of 95 °C for 1 minute, 40 cycles of 95 °C for 4 seconds fol-
lowed by 60 °C for 18 seconds. After running this program the instrument captured images of the various parti-
tion arrays using 2 filter sets: ROX and FAM.
Data availability
The datasets generated or analysed during the current study are available from the corresponding author on 
reasonable request.
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